Top Ten Our Most Popular NASH Podcast Episodes

With over 150,459 downloads since we started in April 2020, and over 680 episodes and conversations, there is a lot to listen to! Here's our Top 10 Most Popular Episodes of Surfing The NASH Tsunami Podcast… Driving The Discussion of Fatty Liver Disease.

Available in your favorite Podcast App.

#1 Most Listened To Epsidode

As of April 10, 2023 - This “conversation” epsiode has been downloaded over 1,550 times.

Top 9 Most Popular Epsiodes

listed in order by published date

Review of Exciting Clinical Trial Press Releases

S3-E48 – Review of Exciting Clinical Trial Press Releases

Stephen Harrison and Mazen Noureddin join regulars Jörn Schattenberg, Louise Campbell and Roger Green to review five recent press releases reporting on trial results from Altimmune, Akero, Poxel, Axcella and Intercept. Dubbed a Wow! episode, the panelists explore some of the most exciting and promising data of the last decade in NASH drug development.

S3-E36 - REGENERATE Redux - Can OCA Succeed With New Data?

S3-E36 – REGENERATE Redux – Can OCA Succeed With New Data?

The Core Four (Stephen Harrison, Jörn Schattenberg, Louise Campbell, and Roger Green) review Intercept Pharmaceuticals’s recent press release on the new REGENERATE findings and ask whether these results are strong enough for OCA to gain approval in NASH fibrosis.

S2-E56 - Day Four at the 2021 TLMdX From AASLD

S2-E56 – Day Four at the 2021 TLMdX From AASLD

Drs. Michael Charlton and Mazen Noureddin and Global Liver Institute Director of Global NASH Programs Jeff McIntyre join Dr. Stephen Harrison, Louise Campbell and Roger Green to review some of the most important and exciting presentations from the final two days of the 2021 TLMdX, the annual meeting of AASLD

S2-E55 - Day Three at the 2021 TLM dX From AASLD

S2-E55 – Day Three at the 2021 TLMdX From AASLD

Profs. Scott Friedman and Michelle Long, Dr. Naim Alkhouri and Global Liver Institute DIrector of Global NASH Programs Jeff McIntyre join Louise Campbell and Roger Green to review some of the most important and exciting presentations from the first three days of the 2021 TLMdX, the annual meeting from AASLD.

Review of Exciting Clinical Trial Press Releases

S3-E48 – Review of Exciting Clinical Trial Press Releases

Stephen Harrison and Mazen Noureddin join regulars Jörn Schattenberg, Louise Campbell and Roger Green to review five recent press releases reporting on trial results from Altimmune, Akero, Poxel, Axcella and Intercept. Dubbed a Wow! episode, the panelists explore some of the most exciting and promising data of the last decade in NASH drug development.

S3-E36 - REGENERATE Redux - Can OCA Succeed With New Data?

S3-E36 – REGENERATE Redux – Can OCA Succeed With New Data?

The Core Four (Stephen Harrison, Jörn Schattenberg, Louise Campbell, and Roger Green) review Intercept Pharmaceuticals’s recent press release on the new REGENERATE findings and ask whether these results are strong enough for OCA to gain approval in NASH fibrosis.

S2-E56 - Day Four at the 2021 TLMdX From AASLD

S2-E56 – Day Four at the 2021 TLMdX From AASLD

Drs. Michael Charlton and Mazen Noureddin and Global Liver Institute Director of Global NASH Programs Jeff McIntyre join Dr. Stephen Harrison, Louise Campbell and Roger Green to review some of the most important and exciting presentations from the final two days of the 2021 TLMdX, the annual meeting of AASLD

S2-E55 - Day Three at the 2021 TLM dX From AASLD

S2-E55 – Day Three at the 2021 TLMdX From AASLD

Profs. Scott Friedman and Michelle Long, Dr. Naim Alkhouri and Global Liver Institute DIrector of Global NASH Programs Jeff McIntyre join Louise Campbell and Roger Green to review some of the most important and exciting presentations from the first three days of the 2021 TLMdX, the annual meeting from AASLD.

Sponsoring Partnerships!

Sponsoring partnerships with SurfingMASH present a multifaceted avenue for companies seeking to amplify their brand presence and engage with targeted audiences.